Vraylar — Net revenues
AbbVie Vraylar — Net revenues decreased by 11.4% to $905M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 18.3%, from $765M to $905M. Over 4 years (FY 2021 to FY 2025), Vraylar — Net revenues shows an upward trend with a 20.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market demand, successful physician adoption, or effective commercial execution, while a decrease may signal increased competition, patent expiration, or loss of market share.
Detailed definition
This metric represents the total gross sales of the specific pharmaceutical product line, adjusted for returns, allowanc...
Peer comparison
Comparable to net product sales reported by other pharmaceutical companies for specific branded drugs or therapeutic franchises.
abbv_segment_vraylar_net_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $432M | $432M | $432M | $427M | $492M | $554M | $565M | $561M | $658M | $751M | $789M | $694M | $774M | $875M | $924M | $765M | $900M | $934M | $1.02B | $905M |
| QoQ Change | — | +0.0% | +0.0% | -1.2% | +15.2% | +12.6% | +2.0% | -0.7% | +17.3% | +14.1% | +5.1% | -12.0% | +11.5% | +13.0% | +5.6% | -17.2% | +17.6% | +3.8% | +9.4% | -11.4% |
| YoY Change | — | — | — | — | +13.9% | +28.2% | +30.8% | +31.4% | +33.7% | +35.6% | +39.6% | +23.7% | +17.6% | +16.5% | +17.1% | +10.2% | +16.3% | +6.7% | +10.6% | +18.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is AbbVie's vraylar — net revenues?
- AbbVie (ABBV) reported vraylar — net revenues of $905M in Q1 2026.
- How has AbbVie's vraylar — net revenues changed year-over-year?
- AbbVie's vraylar — net revenues increased by 18.3% year-over-year, from $765M to $905M.
- What is the long-term trend for AbbVie's vraylar — net revenues?
- Over 4 years (2021 to 2025), AbbVie's vraylar — net revenues has grown at a 20.3% compound annual growth rate (CAGR), from $1.73B to $3.62B.
- What does vraylar — net revenues mean?
- The total net sales generated by the specific pharmaceutical product after accounting for discounts and returns.